Skip to contentS
Starling Oncology, Inc.
S
STLNStarling Oncology, Inc. Q3 2023 · 10-Q
Revenue$82.04M$82.04M+26.3% vs Q3 2022 Net Income-$17.42M-$17.42MN/M vs Q3 2022 EPS Diluted-$0.19-$0.19N/M vs Q3 2022 Operating Income-$13,925,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Starling Oncology, Inc. · CIK 1799191 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$9,240,000N/M Margins · derivedOperating margin-17.0%+14.0 pt vs Q3 2022
Net margin-21.2%−17.1 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 8, 2023 · 39 d after period end